Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 5/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25147551 | 0.74 | OGA (0.44) | VNN1P2RX7 | |
| SCHEMBL23107627 | 0.74 | OGA (0.44) | VNN1P2RX7 | |
| SCHEMBL22992595 | 0.73 | HDAC1 (0.37) | HDAC1 | |
| SCHEMBL16679073 | 0.73 | HDAC3 (0.34) | P2RX7HDAC1HDAC6 | |
| SCHEMBL25287508 | 0.73 | ALDH1A1 (0.36) | HDAC1HDAC6 | |
| SCHEMBL23904557 | 0.72 | VNN1 (0.42) | VNN1P2RX7HDAC1HDAC6IDO1 | |
| SCHEMBL23886593 | 0.71 | VNN1 (0.38) | VNN1P2RX7 | |
| SCHEMBL23886895 | 0.70 | VNN1 (0.41) | VNN1P2RX7IDO1GABRA1 | |
| SCHEMBL30370482 | 0.70 | VNN1 (0.41) | VNN1P2RX7IDO1GABRA1 | |
| SCHEMBL23108622 | 0.70 | VNN1 (0.44) | VNN1P2RX7IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159538-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159538-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | VNN1 4588/4885P2RX7 2055/4885ALOX5AP 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.